The efficacy and safety of a bisoprolol transdermal patch in patients with hypertensive heart disease

The efficacy and safety of a bisoprolol transdermal patch in patients with hypertensive heart disease - The efficacy and safety of a bisoprolol transdermal patch in patients with hypertensive heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018829

Enrollment

Registered

2015-09-01

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure due to hypertensive heart disease

Interventions

To switch oral administration of bisoprolol (2.5mg daily) to bisoprolol transdermal patch (4mg daily) for 3 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who admitted due to hypertensive heart disease and received oral administration of bisoprolol (2.5mg daily) safely.

Exclusion criteria

Exclusion criteria: 1) patients who have contraindication of beta blockers. 2) patients who received hemodialysis. 3) patients who requires re-vascularization. 4) patients who are judged inappropriate for the study by the investigators.

Design outcomes

Primary

Measure	Time frame
1) 24-hour Ambulatory Blood Pressure Monitoring 2) 24-hour Ambulatory Pulse Rate Monitoring 3) UCG (EF, E/e') 4) Plasma BNP levels, plasma catecholamine levels 5) safety	—

Countries

Japan

Contacts

Public ContactTetsuro Miyazaki

Juntendo University School of Medicine Department of Cardiovascular Medicine

tetsuro@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026